通过NOX2途径对血小板活性进行PTH驱动的调节,用于术后的低甲状腺症
Alessandra D'Amico1, Gaia Tabacco2, Cristina Nocella3
1IRCCS Neuromed, Pozzilli, Italy; Department of Health and Life Sciences, European University of Rome, Via degli Aldobrandeschi 190, 00163, Rome, Italy.
术后慢性缺甲状腺症 (HypoPT) 通过增强血小板激活和氧化应激增加心血管风险. 副甲状腺激素 (PTH) 治疗可能会通过NOX2-依赖性途径恶化这些影响,需要密切监测.
科学领域:
- 内分泌学 在内分泌学.
- 心血管医学 心血管医学
- 血液学 血液学 血液学
背景情况:
- 术后慢性缺甲状腺症 (HypoPT) 与心血管风险增加有关.
- 这些机制涉及甲状腺激素 (PTH) 在血小板功能和氧化应激中的潜在作用,有助于动脉血症.
研究的目的:
- 研究PTH对血小板功能和激活的影响.
- 专门研究在HypoPT患者中NOX2-介导的血小板激活.
主要方法:
- 在24名HypoPT患者和40名对照组中进行了横截面研究.
- 评估了血小板聚合,氧化应激生物标志物和血栓形成.
- 在小组中对PTH (1-34) 治疗24个月后评估的变化;在体外测试了PTH (1-34) 对单独血小板的影响.
主要成果:
- 与对照组相比,HypoPT患者的血小板活化增加,氧化应激增加,血栓形成加速.
- PTH (1-34) 治疗在HypoPT患者中放大了这些变化.
- 在体外,PTH (1-34) 通过PTH1R,PKC和NOX2-依赖的ROS生成在HypoPT血小板中增加了氧化应激和血小板聚合.
结论:
- 低PT与血小板活性升高和血栓形成风险有关.
- 通过特定的分子机制,PTH治疗可能会加剧这些变化.
- 强调需要对HypoPT患者进行心血管监测,特别是那些使用PTH类型的患者.
更多相关视频
07:13Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control
Published on: May 24, 2024
07:13Two Techniques to Create Hypoparathyroid Mice: Parathyroidectomy Using GFP Glands and Diphtheria-Toxin-Mediated Parathyroid Ablation
Published on: March 14, 2017
相关概念视频
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Nitric Oxide Signaling Pathway
The Parathyroid Glands
Oxyphil cells, whose functions remain elusive, emerge during late puberty, adding a layer of complexity to the parathyroid gland's intricacies. In contrast, principal parathyroid cells undertake a vital role by...
Hormones and Bone Tissue
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
